The FDA upgraded its recall of metoprolol succinate, a widely prescribed blood pressure drug, from Class III to Class II due to potential carcinogenic risks and dissolution failures, indicating a higher likelihood of adverse health effects. The recall highlights vulnerabilities in global drug suppl…